248
Views
7
CrossRef citations to date
0
Altmetric
Review

Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review

&
Pages 123-131 | Published online: 03 Aug 2016

References

  • ShamloulRGhanemHErectile dysfunctionLancet2013381986115316523040455
  • BraunMWassmerGKlotzTReifenrathBMathersMEngelmannUEpidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’Int J Impot Res200012630531111416833
  • LewisRWFugl-MeyerKSCoronaGDefinitions/epidemiology/risk factors for sexual dysfunctionJ Sex Med201074 Pt 21598160720388160
  • AraujoABTravisonTGGanzPErectile dysfunction and mortalityJ Sex Med2009692445245419538544
  • FeldmanHAGoldsteinIHatzichristouDGKraneRJMcKinlayJBImpotence and its medical and psychosocial correlates: results of the Massachusetts male aging studyJ Urol1994151154618254833
  • BaconCGMittlemanMAKawachiIGiovannucciEGlasserDBRimmEBSexual function in men older than 50 years of age: results from the health professionals follow-up studyAnn Intern Med2003139316116812899583
  • LatiniDMPensonDFLubeckDPWallaceKLHenningJMLueTFLongitudinal differences in disease specific quality of life in men with erectile dysfunction: results from the exploratory comprehensive evaluation of erectile dysfunction studyJ Urol200316941437144212629379
  • MontagueDKJarowJPBroderickGAThe management of erectile dysfunction: an AUA updateJ Urol2005174123023915947645
  • CarvalheiraAAPereiraNMMarocoJForjazVDropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuationJ Sex Med2012992361236922616766
  • SchwartzBGKlonerRADrug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertensionCirculation20101221889520606131
  • LueTFErectile dysfunctionN Engl J Med2000342241802181310853004
  • Saenz de TejadaIMolecular mechanisms for the regulation of penile smooth muscle contractilityInt J Impot Res200214Suppl 1S6S1011850728
  • MontorsiFBrigantiASaloniaAErectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery diseaseEur Urol200344336036412932937
  • NehraAJacksonGMinerMThe Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular diseaseMayo Clin Proc201287876677822862865
  • InmanBASauverJLJacobsonDJA population-based, longitudinal study of erectile dysfunction and future coronary artery diseaseMayo Clin Proc200984210811319181643
  • MehrotraNGuptaMKovarAMeibohmBThe role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapyInt J Impot Res200719325326416988721
  • PryorJLRedmonBNew therapies and delivery mechanisms for treatment of erectile dysfunctionInt J Impot Res200012Suppl 4S158S16211035406
  • GiulianoFAmarEChevallierDMontaigneOJoubertJMChartier-KastlerEHow urologists manage erectile dysfunction after radical prostatectomy: a national survey (REPAIR) by the French urological associationJ Sex Med20085244845718042217
  • LeaAPBrysonHMBalfourJAIntracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunctionDrugs Aging19968156748785470
  • HeatonJPLordingDLiuSNIntracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic menInt J Impot Res200113631732111918246
  • LinetOIOgrincFGEfficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study GroupN Engl J Med1996334148738778596569
  • ManciniMRainaRAgarwalANervaFColpiGMSildenafil citrate vs intracavernous alprostadil for patients with arteriogenic erectile dysfunction: a randomised placebo controlled studyInt J Impot Res200416181214963465
  • ShabsighRPadma-NathanHGittlemanMMcMurrayJKaufmanJGoldsteinIIntracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra)Urology200055447748010736486
  • Garrido AbadPSinues OjasBMartinez BlazquezLConde CaturlaPFernandez ArjonaMSafety and efficacy of intraurethral alprostadil in patients with erectile dysfunction refractory to treatment using phosphodiesterase-5 inhibitorsActas Urol Esp2015391063564026049734
  • YiouRCuninPde la TailleASexual rehabilitation and penile pain associated with intracavernous alprostadil after radical prostatectomyJ Sex Med20118257558220807323
  • YiouREbrahiminiaVMouracadePLingombetOAbbouCSexual quality of life in women partnered with men using intracavernous alprostadil injections after radical prostatectomyJ Sex Med20131051355136223444881
  • PorstHThe rationale for prostaglandin E1 in erectile failure: a survey of worldwide experienceJ Urol199615538028158583582
  • LakinMMMontagueDKVanderBrug MedendorpSTesarLSchoverLRIntracavernous injection therapy: analysis of results and complicationsJ Urol19901436113811412342174
  • HanchanaleVEardleyIAlprostadil for the treatment of impotenceExpert Opin Pharmacother201415342142824369066
  • Padma-NathanHHellstromWJKaiserFETreatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study GroupN Engl J Med19973361178970933
  • PorstHTransurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil – a comparative study in 103 patients with erectile dysfunctionInt J Impot Res1997941871929442415
  • KimSCAhnTYChoiHKMulticenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in KoreaInt J Impot Res20001229710111052635
  • BecherETopical alprostadil cream for the treatment of erectile dysfunctionExpert Opin Pharmacother20045362363215013930
  • WolkaAMRyttingJHReedBLFinninBCThe interaction of the penetration enhancer DDAIP with a phospholipid model membraneInt J Pharm20042711–251015129968
  • YeagerJBeihnRMRetention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunctionInt J Impot Res2005171919515538395
  • McVaryKTPolepalleSRiggiSPelhamRWTopical prostaglandin E1 SEPA gel for the treatment of erectile dysfunctionJ Urol19991623 Pt 172673010458353
  • GoldsteinIPaytonTRSchechterPJA double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunctionUrology200157230130511182341
  • Padma-NathanHSteidleCSalemSTayseNYeagerJHarningRThe efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe EDInt J Impot Res2003151101712605235
  • SteidleCPadma-NathanHSalemSTopical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II programUrology20026061077108212475674
  • Padma-NathanHYeagerJLAn integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patientsUrology200668238639116904458
  • Padma-NathanHMcMurrayJGPullmanWEOn-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunctionInt J Impot Res20011312911313831
  • AndersonPCGommersallLHayneDAryaMPatelHRNew phosphodiesterase inhibitors in the treatment of erectile dysfunctionExpert Opin Pharmacother20045112241224915500370
  • YoungJMVardenafilExpert Opin Investig Drugs2002111014871496
  • RooneyMPfisterWMahoneyMNelsonMYeagerJSteidleCLong-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunctionJ Sex Med20096252053419138370